1 Market Overview

1.1 Product Overview and Scope of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

1.2 Classification of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type

1.2.1 Overview: Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type in 2020

1.2.3 Single-stranded AAV (ssAAV)

1.2.4 Self-complementary AAV (scAAV)

1.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market by Application

1.3.1 Overview: Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hemophilia

1.3.3 Ophthalmology

1.3.4 Lysosomal Storage Disorders

1.3.5 Neurological Disorders

1.3.6 Others

1.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size & Forecast

1.5 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast by Region

1.5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region, (2016-2021)

1.5.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Prospect (2016-2026)

1.5.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Prospect (2016-2026)

1.5.6 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers

1.6.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints

1.6.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Trends Analysis

2 Company Profiles

2.1 BioMarin Pharmaceutical

2.1.1 BioMarin Pharmaceutical Details

2.1.2 BioMarin Pharmaceutical Major Business

2.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.1.4 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 BioMarin Pharmaceutical Recent Developments and Future Plans

2.2 Sangamo Therapeutics

2.2.1 Sangamo Therapeutics Details

2.2.2 Sangamo Therapeutics Major Business

2.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.2.4 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Sangamo Therapeutics Recent Developments and Future Plans

2.3 Amicus Therapeutics

2.3.1 Amicus Therapeutics Details

2.3.2 Amicus Therapeutics Major Business

2.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Amicus Therapeutics Recent Developments and Future Plans

2.4 Roche

2.4.1 Roche Details

2.4.2 Roche Major Business

2.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.4.4 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Roche Recent Developments and Future Plans

2.5 Pfizer

2.5.1 Pfizer Details

2.5.2 Pfizer Major Business

2.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.5.4 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Pfizer Recent Developments and Future Plans

2.6 NightstaRx

2.6.1 NightstaRx Details

2.6.2 NightstaRx Major Business

2.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.6.4 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 NightstaRx Recent Developments and Future Plans

2.7 MeiraGTx

2.7.1 MeiraGTx Details

2.7.2 MeiraGTx Major Business

2.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.7.4 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 MeiraGTx Recent Developments and Future Plans

2.8 Sarepta Therapeutics

2.8.1 Sarepta Therapeutics Details

2.8.2 Sarepta Therapeutics Major Business

2.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.8.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Sarepta Therapeutics Recent Developments and Future Plans

2.9 Neurocrine Biosciences

2.9.1 Neurocrine Biosciences Details

2.9.2 Neurocrine Biosciences Major Business

2.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.9.4 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Neurocrine Biosciences Recent Developments and Future Plans

2.10 Voyager Therapeutics

2.10.1 Voyager Therapeutics Details

2.10.2 Voyager Therapeutics Major Business

2.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.10.4 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Voyager Therapeutics Recent Developments and Future Plans

2.11 Asklepios Biopharmaceutical

2.11.1 Asklepios Biopharmaceutical Details

2.11.2 Asklepios Biopharmaceutical Major Business

2.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

2.11.4 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 Asklepios Biopharmaceutical Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Market Share

3.2.2 Top 10 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Market Share

3.2.3 Market Competition Trend

3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Market Share by Type (2016-2021)

4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Application (2016-2021)

5.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2016-2026)

6.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2026)

6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country

6.3.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2016-2026)

6.3.2 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

6.3.3 Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

6.3.4 Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2016-2026)

7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2026)

7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country

7.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2016-2026)

7.3.2 Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

7.3.3 France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

7.3.5 Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

7.3.6 Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2016-2026)

8.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2026)

8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region

8.3.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Region (2016-2026)

8.3.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

8.3.3 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

8.3.4 South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

8.3.5 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

8.3.7 Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2016-2026)

9.2 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2026)

9.3 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country

9.3.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2016-2026)

9.3.2 Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

9.3.3 Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2016-2026)

10.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2026)

10.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country

10.3.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2016-2026)

10.3.2 Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

10.3.4 UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million) by Region (2016-2021)

Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2021-2026)

Table 6. BioMarin Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 7. BioMarin Pharmaceutical Major Business

Table 8. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 9. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Sangamo Therapeutics Corporate Information, Head Office, and Major Competitors

Table 11. Sangamo Therapeutics Major Business

Table 12. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 13. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Amicus Therapeutics Corporate Information, Head Office, and Major Competitors

Table 15. Amicus Therapeutics Major Business

Table 16. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 17. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Roche Corporate Information, Head Office, and Major Competitors

Table 19. Roche Major Business

Table 20. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 21. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Pfizer Corporate Information, Head Office, and Major Competitors

Table 23. Pfizer Major Business

Table 24. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 25. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. NightstaRx Corporate Information, Head Office, and Major Competitors

Table 27. NightstaRx Major Business

Table 28. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 29. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. MeiraGTx Corporate Information, Head Office, and Major Competitors

Table 31. MeiraGTx Major Business

Table 32. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 33. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Sarepta Therapeutics Corporate Information, Head Office, and Major Competitors

Table 35. Sarepta Therapeutics Major Business

Table 36. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 37. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Neurocrine Biosciences Corporate Information, Head Office, and Major Competitors

Table 39. Neurocrine Biosciences Major Business

Table 40. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 41. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Voyager Therapeutics Corporate Information, Head Office, and Major Competitors

Table 43. Voyager Therapeutics Major Business

Table 44. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 45. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Asklepios Biopharmaceutical Corporate Information, Head Office, and Major Competitors

Table 47. Asklepios Biopharmaceutical Major Business

Table 48. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions

Table 49. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million) by Players (2019-2021)

Table 51. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Players (2019-2021)

Table 52. Breakdown of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Company Type (Tier 1, Tier 2 and Tier 3)

Table 53. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Head Office, Products and Services Provided

Table 54. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Mergers & Acquisitions in the Past Five Years

Table 55. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy New Entrants and Expansion Plans

Table 56. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million) by Type (2016-2021)

Table 57. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Type (2016-2021)

Table 58. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Forecast by Type (2021-2026)

Table 59. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2021)

Table 60. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Forecast by Application (2021-2026)

Table 61. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2016-2021) & (USD Million)

Table 62. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2021-2026) & (USD Million)

Table 63. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2021) & (USD Million)

Table 64. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2021-2026) & (USD Million)

Table 65. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2016-2021) & (USD Million)

Table 66. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2021-2026) & (USD Million)

Table 67. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2016-2021) & (USD Million)

Table 68. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2021-2026) & (USD Million)

Table 69. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2021) & (USD Million)

Table 70. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2021-2026) & (USD Million)

Table 71. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2016-2021) & (USD Million)

Table 72. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2021-2026) & (USD Million)

Table 73. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2016-2021) & (USD Million)

Table 74. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2021-2026) & (USD Million)

Table 75. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2021) & (USD Million)

Table 76. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2021-2026) & (USD Million)

Table 77. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Region (2016-2021) & (USD Million)

Table 78. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Region (2021-2026) & (USD Million)

Table 79. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2016-2021) & (USD Million)

Table 80. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2021-2026) & (USD Million)

Table 81. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2021) & (USD Million)

Table 82. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2021-2026) & (USD Million)

Table 83. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2016-2021) & (USD Million)

Table 84. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2021-2026) & (USD Million)

Table 85. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2016-2021) & (USD Million)

Table 86. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Type (2021-2026) & (USD Million)

Table 87. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2016-2021) & (USD Million)

Table 88. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Application (2021-2026) & (USD Million)

Table 89. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2016-2021) & (USD Million)

Table 90. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Picture

Figure 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type in 2020

Figure 3. Single-stranded AAV (ssAAV)

Figure 4. Self-complementary AAV (scAAV)

Figure 5. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Application in 2020

Figure 6. Hemophilia Picture

Figure 7. Ophthalmology Picture

Figure 8. Lysosomal Storage Disorders Picture

Figure 9. Neurological Disorders Picture

Figure 10. Others Picture

Figure 11. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 12. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Forecast (2016-2026) & (USD Million)

Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2016-2026)

Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region in 2020

Figure 15. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers

Figure 21. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints

Figure 22. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends

Figure 23. BioMarin Pharmaceutical Recent Developments and Future Plans

Figure 24. Sangamo Therapeutics Recent Developments and Future Plans

Figure 25. Amicus Therapeutics Recent Developments and Future Plans

Figure 26. Roche Recent Developments and Future Plans

Figure 27. Pfizer Recent Developments and Future Plans

Figure 28. NightstaRx Recent Developments and Future Plans

Figure 29. MeiraGTx Recent Developments and Future Plans

Figure 30. Sarepta Therapeutics Recent Developments and Future Plans

Figure 31. Neurocrine Biosciences Recent Developments and Future Plans

Figure 32. Voyager Therapeutics Recent Developments and Future Plans

Figure 33. Asklepios Biopharmaceutical Recent Developments and Future Plans

Figure 34. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Players in 2020

Figure 35. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 36. Global Top 3 Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share in 2020

Figure 37. Global Top 10 Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share in 2020

Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 39. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Type in 2020

Figure 40. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Type (2021-2026)

Figure 41. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Application in 2020

Figure 42. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Application (2021-2026)

Figure 43. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2016-2026)

Figure 44. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2016-2026)

Figure 45. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Country (2016-2026)

Figure 46. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 47. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 48. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 49. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2016-2026)

Figure 50. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2016-2026)

Figure 51. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Country (2016-2026)

Figure 52. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. United Kingdom Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 56. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2016-2026)

Figure 58. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2016-2026)

Figure 59. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2016-2026)

Figure 60. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 66. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2016-2026)

Figure 67. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2016-2026)

Figure 68. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Country (2016-2026)

Figure 69. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2016-2026)

Figure 72. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2016-2026)

Figure 73. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Country (2016-2026)

Figure 74. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 75. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 76. UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 77. Methodology

Figure 78. Research Process and Data Source